Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial.
Lancet Haematol
; 9(5): e327-e339, 2022 May.
Article
in En
| MEDLINE
| ID: mdl-35366963
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Lymphoma, Non-Hodgkin
/
Lymphoma, Follicular
/
Lymphoma, Large B-Cell, Diffuse
/
Antibodies, Bispecific
/
Antineoplastic Agents
Type of study:
Clinical_trials
/
Risk_factors_studies
Limits:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Lancet Haematol
Year:
2022
Document type:
Article
Country of publication:
Reino Unido